Background-The BIO14.6 hamster provides a useful model of hereditary cardiomyopathies and muscular dystrophy.
I nherited forms of muscular dystrophy including the Duchenne/Becker muscular dystrophies (DMD/BMD) (ie, dystrophinopathies) and limb-girdle muscular dystrophies commonly affect both skeletal and cardiac muscles. 1 Whereas progressive weakness of neck, trunk, and limb muscles are disabling in such patients, cardiac complications and respiratory failure are major determinants of prognosis. 2, 3 Among the genes mutated in inherited muscular dystrophies, most encode membranecytoskeletal proteins that constitute a macromolecular complex termed the dystrophin-glycoprotein complex (DGC). 1
Clinical Perspective on p 97
BIO14.6 hamsters have a spontaneous genetic deletion around the first exon of the ␦-sarcoglycan (␦SG) gene, 4,5 mutations of which have been linked to human limb-girdle muscular dystrophy type 2F. 1 Because of the absence of ␦SG, BIO14.6 hamsters are unable to form the sarcoglycan (SG) protein complex, a subcomponent of the DGC, on the sarcolemma. Although BIO14.6 hamsters appear normal when born, they die early, with a lifespan of approximately 12 months, primarily caused by the development of severe congestive heart failure. 6 Phenotypic consistency has made the BIO14. 6 hamster a preferred animal model of muscular dystrophy and hereditary cardiomyopathy used for testing new therapies, including gene replacement using viral vectors. [7] [8] [9] [10] [11] [12] However, previous experimental trials of gene therapy (GT) in BIO14.6 hamsters [7] [8] [9] [10] [11] [12] and one trial in mice 13 have focused on the short-or long-term effectiveness of disease prevention by treating SG deficiency early in life (neonatal and young adult animals, up to 9 weeks of age) and the effects of GT in late stage disease, when cardiac and respiratory dysfunction are well established, have not been examined.
In the present study, we delivered the ␦SG gene using an adeno-associated virus serotype 9 (AAV9) vector by intravenous bolus injection, allowing us to test the efficacy of GT in both the cardiac and skeletal muscles in 4-month-old BIO14.6 hamsters with well-established cardiac and respiratory failure. In addition, because a substantial number of cardiomyocytes are lost by 4 months of age 14, 15 and surviving cells are under stress, we added an additional group of BIO14.6 hamsters in which GT with a pseudophosphorylated mutant (S16E) of phospholamban (PLN) was combined with ␦SG GT. Based on our previous studies in BIO14.6 hamsters 16 and postinfarction rats, 17 we expected that the positive inotropic effect of S16EPLN treatment could further enhance any benefits from ␦SG GT alone.
Methods
Additional details are available on-line in "Expanded Methods."
Animals
Male BIO14.6 hamsters and golden Syrian hamsters were obtained from Bio Breeders Inc (Watertown, Mass). All animal-related procedures were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California San Diego.
Viral Vectors
The same ␦SG and S16EPLN expression module that was prepared in our previous studies 11 was used.
GT Procedures
BIO14.6 hamsters (80 to 100 g body weight) were anesthetized with ketamine (100 mg/kg) and xylazine (2.5 mg/kg). Through a small incision in the left inguinal region, the femoral vein was exposed and cannulated with flame-stretched polyethylene tubing (PE-50, Becton-Dickinson, Parsippany, NJ), and AAV9 vectors (8ϫ10 11 viral genome particles per 100 g of body weight) were delivered.
Assessment of Cardiac Function
The methods for transthoracic echocardiographic analysis of left ventricular (LV) function and retrograde LV catheterization using a micromanometer in anesthetized hamsters have been described. 18 Examiners were blinded to the treatments.
Assessment of Respiratory Function
A barometric method of plethymography with continuous flow 19 was used to calculate tidal volume and minute ventilation in spontaneously breathing, nonanesthetized hamsters. Hypercapnia-induced ventilation estimated the additional capacity of animals to respond to a ventilatory stimulus.
Electron Microscopy
The sample preparation procedures have been described. 20 Electron tomography was obtained in thick sections (500 nm) using an A, Time course of the study. The human copy of ␦SG was systemically transferred intravenously to BIO14.6 hamsters at the age of 16 weeks, with or without a pseudophosphorylated mutant PLN (S16EPLN), both carried by an AAV9 vector. B and E, Negative ␦SG immunostaining in LV and quadriceps muscles in placebo (saline)-treated BIO14.6 hamsters. C, D, and F through K, Representative ␦SG immunostaining in various tissues collected from ␦SG/AAV9-treated BIO14.6 hamsters at 28 weeks after GT. D, High-magnification view of a subarea of C (dashed line square). ␦SG induction was confirmed on both the peripheral sarcolemma and the T system (D). Bars, 10 m in B through F; 100 m in G through K.
intermediate high-voltage electron microscopy system (400 kV). The tomographic reconstruction was carried out as described. 20
Immunofluorescent Staining
Snap-frozen heart tissues were cryosectioned, and unfixed specimens were stained using an indirect immunofluorescence strategy as described. 18 
Statistics
Comparison between groups used a mixed-effects linear model or a repeated-measures 2-factor ANOVA with post hoc tests. Values are meanϮSEM, unless stated differently.
Results
The study design is shown in Figure 1A . We treated 16-weekold male BIO14.6 hamsters with intravenous injections of an AAV9 vector carrying a human copy of the ␦SG gene (␦SG/AAV9), ␦SG/AAV9 in combination with S16EPLN carried by an AAV9 vector (S16EPLN/AAV9), and placebo (saline injection). S16EPLN treatment was shown in our previous study to be moderately effective in reducing the degree of heart failure in BIO14.6 hamsters over 7 months. 16 We chose saline treatment as control, based on a finding that echocardiography detected no functional difference between saline-treated animals and animals treated with an AAV9 vector carrying lacZ ␤-D-galactosidase (nϭ5 each group) over 6 months (data not shown).
AAV9 vectors are known to effectively transduce genes in cardiac muscle. [21] [22] [23] [24] Before gene transfer, echocardiographic assessment at 14 weeks of age confirmed that LV function in these BIO14.6 hamsters was substantially depressed compared with age-matched normal golden Syrian hamsters: The percent fractional shortening (%FS) was 31.3Ϯ4.89% in the BIO14.6 (nϭ30) versus 45.8Ϯ2.85% in the normal controls (nϭ6) (PϽ0.001) (Figure 2A , Pre). Enlargement of the LV chamber was not yet statistically significant at this age ( Figure 2B , Pre). However, the LV end-diastolic wall stress estimated by the LV end-diastolic dimension/posterior wall thickness ratio (LVEDd/PWTh) in BIO14.6 hamsters 16 was twice that in normal hamster (7.19Ϯ0.15, nϭ30, versus 3.78Ϯ0.20, normal hamsters, nϭ6, PϽ0.001) ( Figure 2D ). No early mortality or procedure-related health problems were observed after the gene transfer procedure.
The efficiency of ␦SG replacement was nearly 100% both in ventricular cardiomyocytes ( Figure 1C and D) and in fast-twitch skeletal muscles including quadriceps ( Figure 1F ), anterior tibial, and extensor digitorum longus muscle (data not shown). The efficiency was slightly lower in slow-twitch muscles, such as soleus ( Figure 1G ). No ␦SG expression was detectable in nonmuscle organs/tissues including liver, lung, kidney, and brain ( Figure 1H through 1K), and the LV coronary vascular system was devoid of staining.
␦SG GT Halted the Development of Cardiac Failure
After initial echocardiographic studies, the hamsters were randomly separated into subgroups (10 ␦SG/AAV9-treated animals, 10 ␦SG/AAV9and S16EPLN/AAV9-treated, and 10 saline-treated placebo animals) ( Figure 1A ).
Placebo-Treated Group
By 25 weeks after placebo treatment, the general health of the BIO14.6 hamster in the placebo was deteriorating, by developing physical weakness, including markedly reduced spontaneous activity and poor appetite, and clinical signs of congestive heart failure, including dyspnea and anasarca.
One animal died at 18 weeks after the placebo treatment, and the %FS of the other placebo animals had declined by 25 weeks by an average of 56% (to 13.8Ϯ2.13%; nϭ9) ( Figure  2A ). The placebo group developed severe LV chamber dilation ( Figure 2B ). The LV wall thickness remained markedly thinned ( Figure 2C ), and therefore the estimated diastolic wall stress continuously increased in this group ( Figure 2D ). Late echocardiographic studies (49 and 65 weeks after treatment) were not obtained for the placebo group. After 5 randomly selected animals were, as scheduled, removed and used for a hemodynamic study at 28 weeks together with other GT-treated animals, all remaining placebo animals died or were severely morbid by the time of the late echocardiography.
GT Groups
Both BIO14.6 hamsters treated with ␦SG/AAV9 alone and those treated with ␦SG/AAV9 and S16PLN/AAV9 showed vigorous spontaneous activity, maintained good appetite, and displayed no obvious appearance of systemic edema or respiratory distress.
Echocardiography at 25 weeks after GT showed that treatment preserved LV function remarkably well in both treatment groups, demonstrating complete prevention of a decline in the %FS (Figure 2A ), suppression of progressive LV dilation ( Figure 2B ), and a significant increase in diastolic LV wall thickness ( Figure 2C ) which reduced the estimated LV diastolic wall stress relative to the placebo group ( Figure 2D ). The rate of decline in %FS and the rate of LV dilation were significantly smaller in the treatment groups than in the placebo (PϽ0.0001), but there was not a statistically significant difference between the ␦SG/AAV9 treatment alone and the combined treatment of ␦SG/AAV9 and S16PLN/AAV9 (%FS, Pϭ0.21; LVEDd, Pϭ0.10). LV wall thickness was significantly greater at 25 weeks in the treatment groups than in placebo (␦SG/AAV9 alone, Pϭ0.002; ␦SG/AAV9 and S16PLN/AAV9, Pϭ0.0125). Estimated diastolic wall stress did not change significantly after GT (at 25 weeks versus pre: ␦SG/AAV9 alone, Pϭ0.73; ␦SG/AAV9 and S16PLN/AAV9, Pϭ0.17).
Late-stage echocardiography (49 and 65 weeks after GT) showed that a favorable effect of the ␦SG replacement therapy on cardiac function was maintained. Only mild fall in the %FS (Figure 2A ) and gradual LV chamber enlargement ( Figure 2B ) were recognized.
In animal groups treated with ␦SG/AAV9 alone and with ␦SG/AAV9 and S16EPLN/AAV9, a beneficial increase in LV wall thickness observed at 25 weeks (see above) might have served to prevent LVEDd/PWTh from increasing significantly at 49 and 65 weeks ( Figure 2D ).
Hemodynamic Studies
To confirm that prevention of the progressive heart failure phenotypes by GT was due, at least in part, to a direct beneficial effect on LV function and myocardial contractility,
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BIO14.6 hamsters from each treatment group (nϭ5 per group) were subjected to invasive cardiac hemodynamic examination (catheter tip micromanometry) at 28 weeks after GT (at age 44 weeks) ( Figure 3 ). At rest and with a treatment of increasing doses of dobutamine, the maximum first derivative of LV pressure (max LV dP/dt), an index of LV myocardial contractility, was significantly higher in both of the treated groups compared with the placebo group ( Figure  3A ). GT also caused marked enhancement of LV relaxation, reflected in an increase in the peak negative first derivative of LV pressure (min LV dP/dt) ( Figure 3C ) and a shorter time constant of LV pressure decay (tau) ( Figure 3D ), a relatively load-independent measure of relaxation.
␦SG GT Halted Deterioration of Respiratory Function
Most of the placebo-treated BIO14.6 hamsters showed clinical signs of severe respiratory distress before they died. Although lung congestion secondary to heart failure can be the cause of dyspnea, respiratory muscles are among the most severely affected skeletal muscles in BIO14.6 hamsters. 14, 15 Therefore, we combined the 84-to 86-week-old ␦SG/AAV9-treated animals with (nϭ4) and without (nϭ3) S16EPLN treatment and applied whole body plethysmography in awake animals breathing spontaneously. Because untreated BIO14.6 hamsters do not survive to this age, we studied 42-to 46-week-old BIO14.6 hamsters as controls without GT. Golden Syrian hamsters (42 to 46 weeks old) served as normal controls.
Untreated Group
Basal respiratory function (tidal volume and minute ventilation) was mildly depressed in the nontreated group compared with normal hamsters (Figure 4A and B) . However, the hypercapnic ventilatory response to 8% CO 2 was severely impaired. The tidal volume increased by only 45%, compared with highly significant increases (81%) in normal hamsters Chronically improved cardiac contractility and relaxation by ␦SG replacement therapy in BIO14.6 hamsters. BIO14.6 hamsters treated with ␦SG/AAV9 alone or in combination with S16EPLN/ AAV9 (BIO ␦SG and BIO ␦SGϩS16E, respectively) for 28 weeks were subjected to hemodynamic analyses. At rest (dobutamine, 0 g/kg/min) measures of LV contractility (max LV dP/dt) shown in A and relaxation (min LV dP/dt) shown in C were significantly higher in treated animals than in placebo-treated controls. Because min LV dP/dt is sensitive to changes in peak LVP, tau (a relatively load-independent index of relaxation) was also evaluated (D) and improved at rest in the GT groups. Dobutamine enhanced LV systolic and diastolic functions dose-dependently in both placebo and GT groups. Blue dashed lines are pairwise comparisons between animal groups (*PϽ0.05 or "n.s."). #PϽ0.05, versus placebo at rest. Error bars are meanϮSEM; n.s., no significance.
( Figure 4A ). Hypercapnia also inefficiently stimulated minute ventilation of nontreated BIO14.6 hamsters ( Figure 4B ).
GT Group
The basal tidal volume of GT-treated BIO14.6 hamsters was not significantly different from that in normal hamsters ( Figure 4A ). In 8% CO 2 , tidal volume increased by 66% and minute ventilation increased by 117%, to a functional level that was not significantly different from that measured in younger normal hamsters ( Figure 4A and B) . There was no significant difference among the 3 animal groups (normal hamsters, BIO14.6 hamsters, and GT-treated BIO14.6 hamsters) with respect to respiratory frequency, both at rest and after receiving hypercapnic stimulation.
Efficiency of ␦SG Replacement in Respiratory Muscles
GT restored ␦SG in respiratory muscles (diaphragm and the intercostal muscle), and efficiency was nearly 100% in ICM ( Figure 4D and 4H), although ␦SG expression was lower and inhomogeneous in the diaphragm ( Figure 4F and 4J ). In addition, ␣SG and ␤SG immunostaining was observed on the sarcolemma in treated BIO14.6 hamsters (data not shown), confirming that the SG complex was restored on the sarcolemma in respiratory muscles.
␦SG GT Preserved Ultrastructure and Subcellular Components in Cardiac Muscle

Degeneration of the Transverse Tubular System Was Ameliorated
␦SG is known to localize both on the peripheral sarcolemma and along the transverse tubular system (T system) 25, 26 ( Figure 1C and D) . Therefore, using an advanced 3D electron microscopic technology (electron tomography), we characterized T-system abnormality, which was previously reported. 27 As shown in Figure 5D and 5F (see also Video 1), highresolution electron tomography (voxel size: 1.42 nmϫ1.42 nmϫ1.42 nm) revealed a strikingly deformed cardiac T system in placebo-treated BIO14.6 hamsters. Interestingly, multiple cystic invaginations with diameters of 75 to 100 nm were observed on T-system membranes ( Figure 5F ). Such T-system abnormalities were absent in BIO14.6 hamsters treated with ␦SG replacement (Figure 5C, 5E, and 5G) .
DGC Was Reconstituted
Despite preceding focal lytic changes in the myocardium, ␦SG GT effectively recruited and stabilized ␣SG (Figure 6 C and F) , as well as ␤SG and ␥SG (data not shown), on the sarcolemma of surviving cardiomyocytes; the SGs were restored on both the peripheral sarcolemma and the internal sarcolemma of the T system. ␦SG replacement also favorably affected the entire DGC, including the correction of the abnormal distribution of dystrophin at intercalated discs ( Figure 6I and 6H) , which was reported previously. 18 ␤-Dystroglycan (␤-DG) is considered to serve as an intermediate molecule connecting the SG complex and dystrophin 1 ; however, the subcellular distribution of ␤-DG ( Figure 6J through 6L) did not coincide with dystrophin redistribution ( Figure 6G through 6I) .
␦SG GT Prevented Changes in Caveolin-3 Distribution
Because the multiple microcystic invaginations of the T-system membranes found on electron tomography resemble caveolae (see Discussion), we analyzed the distribution of Caveolin-3 (Cav3), a key molecule in the formation of caveolae in cardiac muscle, 28 using immunostaining. Unexpectedly, T-system-associated Cav3 staining was greatly reduced in untreated BIO14.6 hamsters, whereas the punctate staining pattern of Cav3 along the peripheral sarcolemma remained (Figure 7B, 7E, and 7H ). This abnormal Cav3 distribution was not seen in the ␦SG/AAV9-treated BIO14.6 hamsters (Figure 7C, 7F, and 7I) .
GT Prolonged the Lifespan of BIO14.6 Hamsters
As noted above, because of the development of severe symptoms of cardiac and respiratory failures, none of placebo-treated BIO14.6 hamsters (nϭ5) survived to undergo late echocardiography. These animals died of heart failure between 34 and 67 weeks of age. In contrast, there was no animal loss in the GT-treated groups (nϭ10) until 1 animal was found dead at 92 weeks of age, followed by 2 animals at 93 weeks. These animals showed gradual reduction of activity but did not present obvious signs of heart failure or respiratory distress. Kaplan-Meier analysis with the log-rank test revealed significant improvement in animal survival in the treatment groups (each group, Pϭ0.004). The addition of S16EPLN/ AAV9 treatment provided no additional benefit (Pϭ0.48). It should be noted that the late deaths at 92 and 93 weeks are within the reported lifespan of the normal Syrian hamster, 82Ϯ25 weeks in one study 29 and 106Ϯ26 weeks (meanϮ SD) in another study. 30 The remaining 7 animals in the GT group were euthanized at 96 weeks to perform tissue studies.
Discussion
Although previous gene therapy trials treated young BIO14.6 hamsters and ␦SG-null mice before the onset or at an early stage of the disease, 7-13 we chose 16 weeks of age in the current study as the time for GT in BIO14.6 hamsters, when LV dysfunction is moderately severe. 18 In the BIO14.6 hamster, the lytic changes in the myocardium and respiratory muscles become evident by 20 to 40 days of age 15 and subside by 150 to 160 days to be replaced by fibrosis and calcification. 14, 15 The progression of cardiac and skeletal muscle weakness lags somewhat behind histological changes. 14, 15 For example, the LV was not significantly dilated and the %FS was only mildly reduced (37% to 40%) just before treatment in our previous ␦SG GT trial in 7-to 9-week-old BIO14.6 hamsters. 8 In addition, myopathic changes do not appear until 3 months of age in ␦SG-null mice, 31 which were treated in a previous GT study. 13 Accordingly, this study appears to be the first to show that GT at a relatively advanced stage of disease in this form of hereditary cardiac and skeletal myopathy can halt the rapid progression of clinical signs and echocardiographic findings of LV dysfunction, ameliorate many of the structural abnormalities in cardiac muscle, and favorably affect survival.
We consider that the failure of the S16EPLN treatment to provide an additional effect in the current study is primarily due to the overwhelming efficacy of ␦SG GT. In addition, the efficacy of S16EPLN therapy is sensitive to the stoichiometry of sarcoplasmic reticulum calcium-ATPase and native PLN molecules, 16 which might not be optimal in the current study, where recipient BIO14.6 hamsters were much later into treatment than in our earlier study. 16 We believe that this study provides the initial demonstration of a successful in vivo treatment of respiratory dysfunc- tion by GT in a muscular dystrophy model. Because cardiac function and lung function are highly interrelated, 32, 33 we speculate that the improvement of respiratory function found in the current study is probably due to both a direct effect of GT on respiratory muscles and a secondary effect from improved cardiac function.
The study also applied electron tomography 20, 34 and revealed an enormous T-system dilation and multiple small cystic invaginations associated with the T system in placebotreated BIO14.6 hamsters ( Figure 5D and 5F). From their size and shape, we initially speculated that these cystic membrane structures represented caveolae. 35, 36 Caveolae are frequently observed on the peripheral sarcolemma of cardiac myocytes 35 and at the tips of elongating cardiac T-tubules in young mammals. 37 In the past, caveolae were thought to be the precursor of T-tubules. 38 However, this is unlikely in this case, because Cav3, which is prerequisite for caveola formation in striated muscles, 28 was found to be dissociated from the T system in BIO14.6 hamsters ( Figure 7E and 7H) . The cause of Cav3 dislocation is not clear because Cav3 may not be an integral component of the DGC. 39 Nonetheless, it remains possible that the translocation of Cav3 might be a factor leading to disorganization of the cardiac T system in BIO14.6 hamsters, as suggested in studies in humans with limb-girdle muscular dystrophy. 40 There is an increasing awareness of the clinical importance of cardiac involvement in muscular dystrophy. 2, 3 Currently, cardiac and skeletal muscles are often significantly damaged when patients are first diagnosed, despite increasing use of newborn screening. 41 The ␦SG-deficient BIO14.6 hamster used in the current study develops myolysis and progressive weakness in both cardiac and skeletal muscles resembling the clinical manifestation of DMD/BMD. Also, plasma membrane fragility has been suggested as the central disease mechanism of dystroglycanopathies and genetic SG defects, as recently reviewed. 1 Importantly, recent improvements in health care practices have extended the lifespan of DMD/ BMD patients and, as a result, nearly 90% of DMD/BMD patients now die of cardiac or muscular respiratory failure. 2 Accelerated cardiac damage found in dystrophin-deficient mice that were selectively treated for skeletal muscle myopathy further supports the need for cardiac therapy in muscular Figure 6 . Reconstitution of the DGC by ␦SG GT in cardiomyocytes. LV tissues were collected from BIO14.6 hamsters after 28 weeks of treatment with ␦SG/AAV9 alone. The effect of ␦SG/AAV9 treatment (C, F, I, and L) in BIO14.6 hamsters was referenced to placebo treatment (B, E, H, and K) and normal golden Syrian hamsters (A, D, G, and J). D through F, ␣SG staining (red) alone. A through C, Combination of ␣SG staining (red) with membrane staining with WGA (green), which stains both the peripheral sarcolemma and T system, and nuclear staining (nuc, blue) with DAPI. G through I show that dystrophin is expressed on both the peripheral sarcolemma and T system and aberrantly expressed in intercalated discs only in placebotreated BIO14.6 cardiomyocytes (H, arrows). Dystrophin expression in intercalted discs was not accompanied by change in ␤-DG distribution (K). Bars, 10 m. dystrophy. 42 In addition, approximately 25% of all so-called idiopathic cardiomyopathies in humans are genetic, and these individuals might not be identified at an early disease stage by family studies and/or genetic screening. 43 Therefore, we consider that the therapeutic efficacy of relatively late gene replacement demonstrated in the present study carries significant clinical implications for the future of GT in humans, even when cardiac and respiratory dysfunction are well established. Figure 7 . Aberrant distribution of Cav3 in BIO14.6 hamster cardiomyocytes, which was restored by ␦SG replacement. A through C, Cav3 immnostaining (red), together with sarcolemmal staining with WGA (green) and nuclear staining with DAPI (nuc, blue). D through I, Cav3 immnostaining only (red). G through I, High magnification of D through F, respectively (dashed line square). T-system-associated distribution of Cav3 in normal hamsters (arrowheads in G) is largely lost in cardiomyocytes in 28-week placebo-treated BIO4.6 hamsters (E and H). Punctate Cav3 staining on the peripheral sarcolemma (arrows in G through I) is, on the other hand, preserved (H). Abnormal Cav3 distribution was restored at 28 weeks after ␦SG replacement (F and I). Bars, 10 m.
